The therapeutic approach to CNS demyelination associated to ankylosing spondylitis is a complex issue due to the contraindication of TNF inhibitors in demyelinating diseases. Secukinumab, a human IgG1κ monoclonal antibody that binds and inhibits IL-17A, was recently approved for the treatment of ankylosing spondylitis. We report the clinical cases of two patients affected by a CNS demyelinating disease and ankylosing spondylitis who were successfully treated with secukinumab, providing additional evidence of the feasibility of this therapeutic option when the use of TNF inhibitors is discouraged by challenging comorbidities.

Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: Report of two clinical cases / Cortese, Antonio; Lucchetti, Ramona; Altobelli, Alessio; Conte, Antonella; Primavera, Marco; Valesini, Guido; Millefiorini, Enrico; Scrivo, Rossana. - In: MULTIPLE SCLEROSIS AND RELATED DISORDERS. - ISSN 2211-0348. - 35:(2019), pp. 193-195. [10.1016/j.msard.2019.08.006]

Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: Report of two clinical cases

Cortese, Antonio;Lucchetti, Ramona;Altobelli, Alessio;Conte, Antonella;Valesini, Guido;Millefiorini, Enrico;Scrivo, Rossana
2019

Abstract

The therapeutic approach to CNS demyelination associated to ankylosing spondylitis is a complex issue due to the contraindication of TNF inhibitors in demyelinating diseases. Secukinumab, a human IgG1κ monoclonal antibody that binds and inhibits IL-17A, was recently approved for the treatment of ankylosing spondylitis. We report the clinical cases of two patients affected by a CNS demyelinating disease and ankylosing spondylitis who were successfully treated with secukinumab, providing additional evidence of the feasibility of this therapeutic option when the use of TNF inhibitors is discouraged by challenging comorbidities.
2019
Ankylosing spondylitis; Clinical report; Multiple sclerosis; Secukinumab; TNF inhibitors
01 Pubblicazione su rivista::01i Case report
Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: Report of two clinical cases / Cortese, Antonio; Lucchetti, Ramona; Altobelli, Alessio; Conte, Antonella; Primavera, Marco; Valesini, Guido; Millefiorini, Enrico; Scrivo, Rossana. - In: MULTIPLE SCLEROSIS AND RELATED DISORDERS. - ISSN 2211-0348. - 35:(2019), pp. 193-195. [10.1016/j.msard.2019.08.006]
File allegati a questo prodotto
File Dimensione Formato  
Cortese_Secukinumab_2019.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 633.12 kB
Formato Adobe PDF
633.12 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1309785
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 16
social impact